目的: 探讨高血压伴或不伴左心室肥厚(LVH)与健康人群的代谢变化以及可能影响的代谢途径。方法: 招募高血压(HTN)患者30名(HTN组)、高血压伴LVH患者30名(LVH组)和健康志愿者30名(对照组),使用非靶向代谢组学方法获得血浆样本的代谢物谱。结果: 共检测到1 141个代谢物,有43个显著性差异代谢物仅在LVH组与对照组中发生变化,如亮氨酸、腺嘌呤、厚朴酚等,且LVH患者亮氨酸以及腺嘌呤上调。通过KEGG通路分析,共有22种差异代谢产物参与了LVH的代谢途径,与HTN组相比,LVH组亚油酸代谢以及α-亚麻酸(α-linolenic acid,ALA)代谢通路下调。结论: 与健康人相比,LVH患者的代谢物谱有显著不同,表明心肌脂肪酸可能是LVH的保护因素,亮氨酸、腺嘌呤可能是LVH的危险因素,通过α-亚麻酸代谢途径可改善LVH。
Objective: To investigate the metabolic changes and possible metabolic pathways of hypertension with or without left ventricular hypertrophy (LVH) and healthy people. Methods: Thirty patients with hypertension (HTN) (HTN group), 30 patients with hypertension and LVH (LVH group) and 30 healthy volunteers (control group) were recruited. The metabolic profiles of plasma samples were obtained by non-targeted metabolomics. Results: A total of 1141 metabolites were detected, of which 43 were significantly different only in LVH group and control group, such as leucine, adenine, magnolol and so on. Leucine and adenine were up-regulated in LVH patients. According to the analysis of KEGG pathway, a total of 22 differential metabolites were involved in the metabolic pathway of LVH. Compared with HTN group, linoleic acid metabolism and α-linolenic acid (α-linolenicacid,ALA) metabolic pathway were down-regulated in LVH group. Conclusion: Compared with healthy subjects, the metabolic spectrum of patients with LVH is significantly different, indicating that myocardial fatty acids may be protective factors of LVH, leucine and adenine may be risk factors of LVH, and LVH can be improved by α-linolenic acid metabolic pathway.
[1] Yildiz M, Oktay AA, Stewart MH, et al. Left ventricular hypertrophy and hypertension[J]. Prog Cardiovasc Dis, 2020,63(1):10-21.
[2] Jekell A, Nilsson P M, Kahan T. Treatment of hypertensive left ventricular hypertrophy[J]. Curr Pharm Des, 2018,24(37):4391-4396.
[3] Kimura A, Ishida Y, Furuta M, et al. Protective roles of interferon-γ in cardiac hypertrophy induced by sustained pressure overload[J]. J Am Heart Assoc, 2018,7(6):e008145.
[4] Nomura S, Satoh M, Fujita T, et al. Cardiomyocyte gene programs encoding morphological and functional signatures in cardiac hypertrophy and failure[J]. Nat Commun, 2018,9(1):4435.
[5] Singh Sachendra P, Sethi R, Saxena Shailendra K, et al. Role of metabolomics in identifying cardiac hypertrophy:An overview of the past 20 years of development and future perspective[J]. Expert Rev Mol Med, 2021,23:e8.
[6] Gupta A, Houston B. A comprehensive review of the bioenergetics of fatty acid and glucose metabolism in the healthy and failing heart in nondiabetic condition[J]. Heart Fail Rev, 2017,22(6):825-842.
[7] Liu J, Hu J, Tan L, et al. Abnormalities in lysine degradation are involved in early cardiomyocyte hypertrophy development in pressure-overloaded rats[J]. BMC Cardiovasc Disord, 2021,21(1):403.
[8] Li J, Kemp Brandon A, Howell Nancy L, et al. Metabolic changes in spontaneously hypertensive rat hearts precede cardiac dysfunction and left ventricular hypertrophy[J]. J Am Heart Assoc, 2019,8(4):e010926.
[9] Wollenhaupt J, Frisch J, Harlacher E, et al. Pro-oxidative priming but maintained cardiac function in a broad spectrum of murine models of chronic kidney disease[J]. Redox Biol, 2022,56:102459.
[10] Kashioulis P, Lundgren J, Shubbar E, et al. Adenine-induced chronic renal failure in rats: Amodel of chronic renocardiac syndrome with left ventricular diastolic dysfunction but preserved ejection fraction[J]. Kidney Blood Press Res, 2018,43(4):1053-1064.
[11] Diwan V, Small D, Kauter K, et al. Gender differences in adenine-induced chronic kidney disease and cardiovascular complications in rats[J]. Am J Physiol Renal Physiol, 2014,307(11):F1169-F1178.
[12] Louca P, Nogal A, Moskal A, et al. Cross-sectional blood metabolite markers of hypertension: A multicohort analysis of 44, 306 individuals from the consortium of metabolomics studies[J]. Metabolites, 2022,12(7):601.
[13] Bednarski Tomasz K, Duda Monika K, Dobrzyn P. Alterations of lipid metabolism in the heart in spontaneously hypertensive rats precedes left ventricular hypertrophy and cardiac dysfunction[J]. Cells, 2022,11(19):3032.
[14] Kim Oh Y, Young-Sang J, Cho Y, et al. Altered heart and kidney phospholipid fatty acid composition are associated with cardiac hypertrophy in hypertensive rats[J]. Clin Biochem, 2013,46(12):1111-1117.
[15] Jeckel Kimberly M, Bouma Gerrit J, Hess Ann M, et al. Dietary fatty acids alter left ventricular myocardial gene expression in wistar rats[J]. Nutr Res, 2014,34(8):694-706.
[16] Sala-Vila A, Fleming J, Kris-Etherton P, et al. Impact of α-linolenic acid, the vegetable ω-3 fatty acid, on cardiovascular disease and cognition[J]. Adv Nutr, 2022,13(5):1584-1602.
[17] Poudyal H, Panchal Sunil K, Waanders J, et al. Lipid redistribution by α-linolenic acid-rich chia seed inhibits stearoyl-coa desaturase-1 and induces cardiac and hepatic protection in diet-induced obese rats[J]. J Nutr Biochem, 2012,23(2):153-162.
[18] Poudyal H, Kumar Senthil A, Iyer A, et al. Responses to oleic, linoleic and α-linolenic acids in high-carbohydrate, high-fat diet-induced metabolic syndrome in rats[J]. J Nutr Biochem, 2013,24(7):1381-1392.
[19] Pierre-Andre B, Holloway Tanya M, Whitfield J, et al. α-linolenic acid and exercise training independently, and additively, decrease blood pressure and prevent diastolic dysfunction in obese zucker rats[J]. J Physiol, 2017,595(13):4351-4364.
